logo
logo

Thoma Bravo Announces Strategic Growth Investment In Bluesight To Support The Company'S Acquisition Of Medacist

Jul 17, 2023•almost 2 years ago

Acquiring Company

Thoma Bravo

Acquired Company

Medacist

Financial ServicesMachine LearningArtificial IntelligenceBiotechnologyHealth CareAnalytics

Description

Thoma Bravo, a leading software investment firm, today announced the closing of a strategic growth investment in Bluesight, the Medication IntelligenceTM Company. The investment is expected to further enhance Bluesight's drug diversion prevention offerings through its acquisition of Medacist, a pioneer in drug diversion monitoring, and continue to grow Bluesight's inventory management and spend optimization offerings. Current investor New Leaf Ventures will remain invested in the business. Financial terms of the transaction were not disclosed.

Company Information

Company

Thoma Bravo

About

Thoma Bravo is one of the largest private equity firms in the world, with more than $83 billion in assets under management as of June 30, 2021. The firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging the firm’s deep sector expertise and proven strategic and operational capabilities, Thoma Bravo collaborates with its portfolio companies to implement operating best practices, drive growth initiatives and make accretive acquisitions intended to accelerate revenue and earnings. Over the past 20 years, the firm has acquired more than 325 companies representing over $100 billion in enterprise value. The firm has offices in Chicago, Miami and San Francisco. For more information, visit thomabravo.com.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed